However they more commonly originate from the metaphysis, lack calcification and have a different histologic organization pattern. [5] Other differential diagnoses for chondroblastoma consist of giant cell tumors , bone cysts , eosinophilic granulomas , clear cell chondrosarcomas , and enchondromas (this list is not exhaustive). [1] [5] Treatment [ edit ] Chondroblastoma has not been known to spontaneously heal and the standard treatment is surgical curettage of the lesion with bone grafting . [1] To prevent recurrence or complications it is important to excise the entire tumor following strict oncologic criteria . [1] [5] However, in skeletally immature patients intraoperative fluoroscopy may be helpful to avoid destruction of the epiphyseal plate. [1] In patients who are near the end of skeletal growth, complete curettage of the growth plate is an option. [1] In addition to curettage, electric or chemical cauterization (via phenol ) can be used as well as cryotherapy and wide or marginal resection . [1] [5] Depending on the size of the subsequent defect, autograft or allograft bone grafts are the preferred filling materials. [1] [5] Other options include substituting polymethylmethacrylate (PMMA) or fat implantation in place of the bone graft. [1] [3] [5] The work of Ramappa et al suggests that packing with PMMA may be a more optimal choice because the heat of polymerization of the cement is thought to kill any remaining lesion. [1] [3] Both radiotherapy and chemotherapy are not commonly used. [1] [5] Radiotherapy has been implemented in chondroblastoma cases that are at increased risk of being more aggressive and are suspected of malignant transformation . [1] [5] Furthermore, radiofrequency ablation has been used, but is typically most successful for small chondroblastoma lesions (approximately 1.5 cm). [1] Treatment with radiofrequency ablation is highly dependent on size and location due to the increased risk of larger, weight-bearing lesions being at an increased risk for articular collapse and recurrence. [1] [5] Overall, the success and method of treatment is highly dependent upon the location and size of the chondroblastoma. [1] [4] [5] Prognosis [ edit ] Although not specific to one mode of management, lesion size, patient sex, or follow-up, the recurrence rate for chondroblastoma is relatively high, and has been shown in select studies to be dependent upon the anatomical location, method of treatment, and biological aggressiveness of the initial lesion. [1] [3] [5] The rate of recurrence is highly variable, ranging between 5% and 40%, as study results are generally inconclusive. [1] However, local recurrence for long bone lesions is around 10%, with chondroblastoma in flat bones having higher recurrence and more complications. [1] [5] Recurrences are more common in cases involving an open epiphyseal plate where they can be attributed to inadequate curettage to avoid damage. [1] [5] Lesions of the proximal femur are particularly problematic because of difficulties accessing the femoral head for complete excision . [1] Chondroblastoma may recur in the soft tissue surrounding the initial lesion, especially in the case of incomplete curettage. [1] Recurrences have been shown to occur between 5 months and 7 years after initial treatment and are generally treated with repeat curettage and excision of affected soft-tissue. [1] [5] No histological differences have been seen between recurrent and non-recurrent chondroblastomas. [1] [4] [6] Rarely, more aggressive chondroblastomas can metastasize . [1] The most common location for metastases is the lung , with some cases also involving secondary bone sites, soft tissue, skin, or the liver . [1] [5] The prevalence of metastatic chondroblastoma, however, is quite low and is believed to be less than 1%. [1] There is no relationship established between metastasis and previous surgery, non-surgical treatment, anatomical location, or patient age. [1] Survival of patients with metastatic lesions is better when the metastases are surgically resectable, as chemotherapy has been shown to have little to no benefit. [1] Prognosis is bleak for patients with malignant chondroblastomas that are resistant to surgery, radiation, and chemotherapy. [5] However, patients with resectable metastases have survived for several years following diagnosis. [1] While recurrence is the most common complication of chondroblastoma other issues include post-surgery infection , degenerative joint disease , pathological fractures, failure of bone grafts, pre-mature epiphyseal closure , functional impairment, and malignant transformation. [1] [5] Complications are less common in patients presenting with chondroblastoma in accessible areas. [1] Overall, patients with more classical chondroblastoma (appearing in long bones, typical presentation) have better prognoses than patients with atypical chondroblastoma (flat bones, skull, etc.). [1] [3] [4] [5] [6] History [ edit ] Chondroblastoma was first described in 1927 as a cartilage-containing giant cell tumor by Kolodny but later characterized by Codman in 1931. [1] [4] Codman believed chondroblastoma to be an "epiphyseal chondromatous giant cell tumor" in the proximal humerus . [1] [3] This view was changed later by a comprehensive review completed by Jaffe and Lichtenstein in 1942 of similar tumors in other locations than the proximal humerus. [1] [4] They re-defined the tumor as a benign chondroblastoma of the bone that is separate from giant cell tumors. [1] [5] However, chondroblastoma of the proximal humerus is still sometimes referred to as Codman’s Tumor. [1] [3] [4] References [ edit ] ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq De Mattos, Camilia B. ... Web. 5 Dec. 2015. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah Damron, Timothy A.
H3-3B,
H3-3A,
SOX9,
ACAN,
SETD2,
SATB2,
CKAP4,
PDPN,
TP63,
NSD2,
UVRAG,
TP53,
SMARCB1,
BMP2,
S100B,
S100A1,
RPE65,
PTGS2,
IDH2,
FGFR1,
EXT1,
BCOR
